Zura Bio (ZURA) Stock Price

Zura Bio Ltd. develops novel medicines for immune disorders, focusing on clinical-stage therapeutics such as ZB-168 and torudokimab. ZB-168, an anti-IL7Rα inhibitor, targets diseases linked to IL7 and TSLP pathways, building on Phase Ib data in type 1 diabetes. Torudokimab, a monoclonal antibody neutralizing IL33, is in phase II development. The company monetizes through advancing these assets into later-stage clinical programs, leveraging their therapeutic potential for immune-related conditions. Zura Bio Ltd. generates revenue by progressing its pipeline candidates toward regulatory approval and commercialization. The firm's portfolio includes ZB-168 for immune disorders with a demonstrated safety profile in type 1 diabetes, and torudokimab targeting IL33-related conditions. These assets are developed for specific therapeutic indications, with ZB-168 expanding into new immune disorder applications based on existing clinical data. The company's primary revenue stream comes from the advancement of its clinical-stage assets, including ZB-168 and torudokimab, into phase II development. ZB-168 is positioned for diseases involving IL7 and TSLP pathways, while torudokimab addresses IL33-related conditions. Both products are developed for immune disorder treatments, with ZB-168 leveraging Phase Ib data in type 1 diabetes to support further development.